Morehouse School of Medicine and Freenome Present Research Demonstrating High Enrollment Rates for African Americans in Clinical Trial

New study finds African American recruitment at a historically black college and university (HBCU)
matches other patient populations.

Morehouse is a leading site for enrollment for PREEMPT CRC,
Freenome's large, registrational study for colorectal cancer screening.

SOUTH SAN FRANCISCO, Calif., Oct. 27, 2021 /PRNewswire/ -- Freenome, a privately held biotech company, together with researchers from Morehouse School of Medicine, presented research earlier this week at the American College of Gastroenterology (ACG) annual meeting that demonstrates rates of enrollment in a colorectal cancer screening study of African Americans (AAs) from an HBCU is similar to Caucasian enrollment at other sites.

PREEMPT CRC, Freenome's multi-center clinical study on colorectal cancer, is in the final stages of enrollment. The study leverages a novel hybrid model that includes both virtual and traditional recruitment to reach underserved communities and ensure a diverse and representative population. With an estimated enrollment of more than 25,000 individuals, PREEMPT CRC represents the largest registrational study to date for a CRC screening test for asymptomatic, average risk adults in the United States. 

View Full Press Release